Onconetix pivots to Proclarix as severe cash crunch, Ocuvex merger looms

Snapshot - Onconetix, Inc. (NASDAQ: BWV)

What's happening inside: management has pivoted to commercializing Proclarix (Proteomedix acquisition) while abandoning ENTADFI commercialization; the company faces acute liquidity stress and repeated forbearance/waivers with creditor Veru. A potential merger with Ocuvex was announced (July 16, 2025) that would materially re‑shape ownership if completed.

Key facts & figures (straight, factual)

- Cash: $283,515 at June 30, 2025 (cash ~ $0.2M as of Aug 13, 2025 per MD&A)

- Total assets: $19,119,036 (June 30, 2025) vs $28,181,563 (Dec 31, 2024)

- Total liabilities: $12,765,832 (June 30, 2025)

- Working capital deficit: ~ $11.8 million (company statement)

- Notes payable, current (net): $8,731,571 (June 30, 2025)

- Series C redeemable preferred: 2,130 shares outstanding; carrying value $443,443 (June 30, 2025)

- Goodwill: $18,123,296 (June 30, 2025) - impaired from $27,048,973 (Dec 31, 2024)

- Revenue: Q2 2025 $106,494 vs Q2 2024 $704,848 (down 84.9%); YTD 2025 $208,124 vs YTD 2024 $1,405,281 (down 85.2%)

- Gross profit: Q2 2025 $70,503; YTD 2025 $116,335

- Total operating expenses: Q2 2025 $2,005,921 vs Q2 2024 $13,715,735

- Goodwill impairment charges: Q2 2025 $594,000; YTD 2025 $11,512,000 (material)

- Net loss: Q2 2025 $(2,372,442) vs Q2 2024 $(14,306,704); YTD 2025 $(10,918,327) vs YTD 2024 $(25,425,276)

- Loss per share (basic & diluted): Q2 2025 $(4.76); YTD $(31.67) - note weighted average shares changed materially (567,648 for Q2 2025 vs 6,528 for Q2 2024)

- Cash used in operating activities: YTD 2025 $(3,409,976)

- Cash provided by financing YTD 2025: $3,614,828 - includes ELOC proceeds of $6,391,655 (YTD)

- Change in fair value - subscription agreement (related party): YTD 2025 gain $3,127,962 (previous periods large swings noted)

- Contingent warrant liabilities: $53,113 (June 30, 2025)

Positive aspects of the income statement and operations

- There is recurring product revenue (Proclarix), entirely EU‑centric in the quarter ($104,213 of $106,494 in Q2 2025) - proof of commercial sales, however modest.

- Gross profit is positive on the small revenue base (Q2 gross profit $70,503), indicating unit economics are not currently negative for product sales.

- Management reduced SG&A materially (selling, general & administrative fell ~31% YoY Q2 and ~46% YTD) - cost discipline is active.

- Non‑cash recoveries in the period (change in fair value of subscription liability, gain on forgiveness of accounts payable $944,694 YTD) improved reported results vs cash operating burn.

- LabCorp license for U.S. commercialization offers a clear pathway to U.S. revenue and milestone/royalty upside (royalties 5-10% and $2.5M in milestones disclosed).

Negative aspects of the income statement and risks

- Revenue collapse: ~85% decline YoY (both Q2 and YTD) - ramp risk and concentrated customer exposure (Customer A generated ~98% of product sales Q2 2025).

- Large non‑cash impairments: goodwill impairment YTD $11.5M - indicates prior acquisition value severely discounted by market/operational realities.

- Persistent net losses: YTD net loss $10.9M and accumulated deficit $128.1M - loss trajectory remains substantial.

- Cash and liquidity are critical: $283,515 cash at quarter end, $0.2M reported Aug 13, 2025; working capital deficit ~ $11.8M; significant short‑term debt/notes due - substantial doubt about going concern without new capital.

- Heavy reliance on third parties (LabCorp for U.S., third‑party manufacturing) and on the ELOC and one large investor - concentration risk.

- Series C deemed dividends and redemption mechanics are dilutive/expensive (deemed dividend YTD $1,498,595); conversion mechanics and PIPE blockers complicate financing.

- Repeated forbearance and waiver agreements with Veru over two $5M notes - creditor pressure is real and payment obligations remain near term.

- Material weaknesses in internal controls disclosed - raises risk of financial reporting errors and oversight gaps.

Bottom line (straight): Onconetix has a commercial product (Proclarix) generating small EU revenue and positive gross margin, but balance sheet and cash flow are the dominant story: severe liquidity strain, large impairments, concentrated revenue, and sizeable short‑term debt. Management is pursuing financing (ELOC draws, Keystone notes), a potential Ocuvex merger, and license relationships (LabCorp) to bridge the gap - but absent timely new capital or material revenue ramp, the company faces significant going‑concern risk.

If you want, I can turn this into a one‑page investor summary for distribution (with a simple risk/return scorecard) or pull the exact timeline of debt maturities and financing availability.